Investing.com - Las acciones de Novo Nordisk subieron el martes después de que la compañía obtuviera la aprobación estadounidense para su píldora de pérdida de peso GLP-1, marcando la primera vez que ...
¿Por qué es importante? Se trata del primer medicamento GLP-1 de forma oral que ya está aprobado oficialmente en Estados ...
La FDA ha aprobado la versión oral de Wegovy para el control del peso. Conoce los resultados del ensayo Oasis 4, su ...
Danish drugmaker Novo Nordisk A/S was at the forefront of the weight-loss injection boom as people discovered that its ...
Novo Nordisk A/S secures FDA nod for oral Wegovy, expanding obesity treatment options. Click for how oral GLP-1 therapies ...
Stocktwits on MSN
The 2025 weight-loss drug gold rush: How Eli Lilly pulled ahead, Novo hit a snag — and a swarm of biotech underdogs are closing in
Global obesity-drug sales could exceed $130–150B by the mid-2030s, driven by GLP-1/GIP drugs and expanding access beyond the U.S. ・Lilly strengthens its leadership with a deep pipeline, while Novo ...
CHONGQING, CHINA - SEPTEMBER 10: In this photo illustration, the logo of Novo Nordisk is displayed on a smartphone screen on September 10, 2025 in Chongqing, China. The maker of Wegovy and Ozempic, ...
The maker of the blockbuster weight loss and diabetes drugs Wegovy and Ozempic have cut the prices for most versions of these medications. Novo Nordisk dropped the price for injectable Wegovy and ...
The U.S. Food and Drug Administration's approval of an oral version of Novo Nordisk's weight-loss drug Wegovy could ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback